Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase. Wan EYF, Wang B, Mathur S, Chan CIY, et al. J Infect 2023 Feb 21:S0163-4453(23)00117-2. doi: 10.1016/j.jinf.2023.

Read + Share

Amedeo Smart

Independent Medical Education

Wan EYF, Wang B, Mathur S, Chan CIY, et al. Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase. J Infect 2023 Feb 21:S0163-4453(23)00117-2. doi: 10.1016/j.jinf.2023.
PMID: 36822409